Kenneth Kim, MD, WCCT Global CEO said, “I am pleased to have Dr. Ababa re-join our team to further expand our early clinical development capabilities here at WCCT Global”
Costa Mesa, California (PRWEB) December 19, 2012
WCCT Global, LLC, a contract research organization (CRO) supporting Phase I - IV biopharmaceutical and device development, today welcomes Michelle Ababa, MD back to the medical team after four years. Ababa will serve primarily as principal investigator for many of the Asian Bridging trials already in the pipeline for 2013. Dr. Michelle Ababa has an extensive background working directly as the principal investigator in many ethnobridging studies including phase 1 Japanese bridging clinical trials and Chinese bridging clinical trials including first in human trials with both small molecules and biologics. Her experience in pediatrics, asthma and HCV early development trials also fits well with the WCCT Global research experience portfolio. She has a strong background in family medicine and is board certified which has led her to work with well-known organizations. Her expertise in early phase ethnobridging studies is a key asset to the team. Kenneth Kim, MD, WCCT Global CEO said, “I am pleased to have Dr. Ababa re-join our team to further expand our early clinical development capabilities here at WCCT Global”
More about WCCT Global’s full service clinical program:
WCCT Global is a multi-site, full service global provider of outsourced early drug development services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision; “With compassion for people, we strive to for tomorrow’s therapies to be available today.” drives the focus of the staff and growth strategy for the company. As a drug development partner, WCCT Global partners with domestic and foreign innovator companies who need regulatory, program management, and strategic consulting support from First-in-Man thru the proof of concept stage with an emphasis on overseeing and executing on trials in special disease populations, ethno-bridging volunteers, and cardiac safety studies.
To request more information about WCCT Global, CLICK HERE